Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) — ECLIPSE  

HCV Infection Clinical Trial

Official title: Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations

Status Withdrawn

Clinical Trial Summary

Hepatitis C (HCV) is a chronic infection with significant morbidity and mortality. The development of directly acting antivirals (DAA) has dramatically improved the cure rate of HCV treatment. People who experience incarceration are disproportionately infected and often involved in ongoing transmission of disease. However, despite availability of effective treatment, people who experience incarceration are often unable to access this curative therapy, and are often not readily engaged in medical care upon release. This perpetuates transmission and progression of disease in an incredibly high risk, marginalized population. Therefore, in order to effectively eliminate HCV, it is imperative that the epidemic of HCV in prisons is addressed, and that models of care are established for treatment of HCV in incarcerated individuals, both during and after incarceration. As such, the investigators propose a comprehensive model of care to engage incarcerated individuals in treatment of HCV upon release from prison. This care is provided in conjunction with collocated services to prevent HCV reinfection, including opioid agonist therapy. This pilot trial will demonstrate whether a comprehensive model of care can effectively cure HCV in recently incarcerated individuals, while simultaneously treating opioid use disorder and preventing HCV reinfection.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• HCV Infection
• Hepatitis C

• NCT number: NCT04235049
• Study type: Interventional
• Source: University of Maryland, Baltimore
• Status: Withdrawn
• Phase: Phase 4
• Start date: October 1, 2021
• Completion date: October 30, 2024